Theratechnologies Inc.

Amolyt Pharma

Thierry Abribat

Denis Gravel

Soraya Allas

Andre De Villers

Alcide Chapdelaine

David Clemmons

Thomas Delale

Krishna G Peri

Abdelkrim Habi

Gang Xi

Stephane Milano

Michel Julien

Bruno Lussier

Luc Vachon

The present technology generally relates to compounds, in particular peptides comprising the heparin-binding domain (HBD) of insulin-like growth factor binding protein-2 (IGFBP-2) for the modulation of metabolic disorders. The present technology also generally relates to uses of such compounds in methods for preventing and/or treating metabolic disorders and in compositions and formulations for such uses.

Heparin-binding domain of IGFBP-2 in the treatment of metabolic disorders

The present technology generally relates to peptides of IGFBP-2 that may be used to improve bone disorders. The present technology also generally relates to uses of such peptides in methods for preventing or treating bone disorders and to compositions for such uses.

Compounds, compositions and uses thereof for improvement of bone disorders

The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.

GH secretagogues and uses thereof

The present invention provides methods for using growth hormone releasing factor analogs of the formula (A), X-GRF Peptide, and pharmaceutically acceptable salts thereof, for increasing muscle function in a subject. Also disclosed herein are corresponding methods, packages and compositions.

Use of growth hormone releasing factor analogs in treating patients suffering from wasting

The present invention relates to a GLP-1 peptide having the following formula, or a pharmaceutically acceptable salt thereof:X-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-lle-Ala-Trp-Leu-val-Lys-Gly-Arg-Y (SEQ ID NO. 1)

Modified GLP-1 peptides with increased biological potency

Growing community of inventors

St-Foy-les-Lyon, France

Thierry Abribat